430 related articles for article (PubMed ID: 19020197)
1. Strategies for preventing respiratory syncytial virus.
Forbes M
Am J Health Syst Pharm; 2008 Dec; 65(23 Suppl 8):S13-9. PubMed ID: 19020197
[TBL] [Abstract][Full Text] [Related]
2. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation.
Wang D; Cummins C; Bayliss S; Sandercock J; Burls A
Health Technol Assess; 2008 Dec; 12(36):iii, ix-x, 1-86. PubMed ID: 19049692
[TBL] [Abstract][Full Text] [Related]
3. A review of palivizumab and emerging therapies for respiratory syncytial virus.
Shadman KA; Wald ER
Expert Opin Biol Ther; 2011 Nov; 11(11):1455-67. PubMed ID: 21831008
[TBL] [Abstract][Full Text] [Related]
4. Prevention of respiratory syncytial virus infections in high-risk infants by monoclonal antibody (palivizumab).
Groothuis JR; Nishida H
Pediatr Int; 2002 Jun; 44(3):235-41. PubMed ID: 11982888
[TBL] [Abstract][Full Text] [Related]
5. Restrictive Palivizumab Use Does Not Lead to Increased Morbidity and Mortality in Pediatric Hematopoietic Stem Cell Transplantation Patients.
Teusink-Cross A; Davies SM; Danziger-Isakov L; El-Bietar J; Grimley MS
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1904-1906. PubMed ID: 27422147
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.
Andabaka T; Nickerson JW; Rojas-Reyes MX; Rueda JD; Bacic Vrca V; Barsic B
Cochrane Database Syst Rev; 2013 Apr; (4):CD006602. PubMed ID: 23633336
[TBL] [Abstract][Full Text] [Related]
7. Respiratory syncytial virus: seasonal data for regions of Florida and implications for palivizumab.
Bauman J; Eggleston M; Oquist N; Malinoski F
South Med J; 2007 Jul; 100(7):669-76. PubMed ID: 17639745
[TBL] [Abstract][Full Text] [Related]
8. Respiratory syncytial virus (RSV) immune globulin and palivizumab for prevention of RSV infection.
Robinson RF; Nahata MC
Am J Health Syst Pharm; 2000 Feb; 57(3):259-64. PubMed ID: 10674778
[TBL] [Abstract][Full Text] [Related]
9. Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit?
Geskey JM; Ceneviva GD; Brummel GL; Graff GR; Javier MC
Clin Ther; 2004 Dec; 26(12):2130-7. PubMed ID: 15823776
[TBL] [Abstract][Full Text] [Related]
10. Current strategies in the prevention of respiratory syncytial virus disease.
Paes BA
Paediatr Respir Rev; 2003 Mar; 4(1):21-7. PubMed ID: 12615029
[TBL] [Abstract][Full Text] [Related]
11. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn.
Pediatrics; 1998 Nov; 102(5):1211-6. PubMed ID: 9794957
[TBL] [Abstract][Full Text] [Related]
12. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
Meissner HC; Long SS;
Pediatrics; 2003 Dec; 112(6 Pt 1):1447-52. PubMed ID: 14654628
[TBL] [Abstract][Full Text] [Related]
13. Prevention and treatment of respiratory syncytial virus infection in infants: an update.
Venkatesh MP; Weisman LE
Expert Rev Vaccines; 2006 Apr; 5(2):261-8. PubMed ID: 16608425
[TBL] [Abstract][Full Text] [Related]
14. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn
Pediatrics; 2003 Dec; 112(6 Pt 1):1442-6. PubMed ID: 14654627
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and optimization of palivizumab injection regimens against respiratory syncytial virus infection.
Gutfraind A; Galvani AP; Meyers LA
JAMA Pediatr; 2015 Apr; 169(4):341-8. PubMed ID: 25706618
[TBL] [Abstract][Full Text] [Related]
16. [Palivizumab--a monoclonal antibody for passive immunoprophylaxis of respiratory syncytial virus infections].
Scholz H
Z Geburtshilfe Neonatol; 2000; 204(3):120-2. PubMed ID: 10909169
[TBL] [Abstract][Full Text] [Related]
17. New strategies for control of respiratory syncytial virus infection.
Nokes JD; Cane PA
Curr Opin Infect Dis; 2008 Dec; 21(6):639-43. PubMed ID: 18978532
[TBL] [Abstract][Full Text] [Related]
18. Prevention of respiratory syncytial virus infection with palivizumab.
Thomas M; Bedford-Russell A; Sharland M
Monaldi Arch Chest Dis; 2000 Aug; 55(4):333-8. PubMed ID: 11057088
[TBL] [Abstract][Full Text] [Related]
19. Respiratory Syncytial Virus Disease: Immunoprophylaxis Policy Review and Public Health Concerns in Preterm and Young Infants.
Staebler S; Blake S
Policy Polit Nurs Pract; 2021 Feb; 22(1):41-50. PubMed ID: 33050785
[TBL] [Abstract][Full Text] [Related]
20. Clinical and pharmacological aspects of immunoprophylaxis for respiratory syncytial virus infection in high-risk infants.
Lanari M; Silvestri M; Rossi GA
Curr Drug Metab; 2013 Feb; 14(2):216-25. PubMed ID: 22935064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
